|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431 |
|
2023 Conference Publication Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001)Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Weickhardt, Andrew James, Lee, Sze Ting, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D. and Emmett, Louise (2023). Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Journal Article Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Ho, Bao, Yam, Andrew O., Wilson, Peter, Niman, Remy, Ayers, Maria, Sharma, Shikha, Hickey, Adam, Eu, Peter, Stockler, Martin, Martin, Andrew J., Joshua, Anthony M., Nguyen, Andrew and Emmett, Louise (2023). Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). Journal of Nuclear Medicine, 64 (2), 221-226. doi: 10.2967/jnumed.122.264398 |
|
2023 Journal Article Nicotinamide for Skin-Cancer Chemoprevention in TransplantationSchmults, Chrysalyne D., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily, Trepanowski, Nicole, Kim, Daniel Y., Hartman, Rebecca I., Allen, Nicholas C., Martin, Andrew J. and Damian, Diona L. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. New England Journal of Medicine, 388 (26), 2493-2495. doi: 10.1056/NEJMc2303841 |
|
2023 Journal Article The prognostic value of posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a phase I/II trial (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Nguyen, Andrew, Yam, Andrew O., Wilson, Peter, Niman, Remy, Ayers, Maria, Sharma, Shikha, Eu, Peter, Martin, Andrew J., Stockler, Martin R., Joshua, Anthony M. and Emmett, Louise (2023). The prognostic value of posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a phase I/II trial (LuPIN). Journal of Nuclear Medicine, 64 (1), 69-74. doi: 10.2967/jnumed.122.264104 |
|
2022 Journal Article Estimation of the treatment effect following a clinical trial that stopped early for benefitMarschner, Ian C., Schou, Manjula and Martin, Andrew J. (2022). Estimation of the treatment effect following a clinical trial that stopped early for benefit. Statistical Methods in Medical Research, 31 (12), 2456-2469. doi: 10.1177/09622802221122445 |
|
2022 Journal Article Changes to design and analysis elements of research plans during randomised controlled trials in AustraliaCoskinas, Xanthi, Simes, R. John and Martin, Andrew J. (2022). Changes to design and analysis elements of research plans during randomised controlled trials in Australia. Medical Journal of Australia, 217 (10), 526-531. doi: 10.5694/mja2.51715 |
|
2022 Journal Article PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trialButeau, James P, Martin, Andrew J, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen, Joshua, Anthony M, Francis, Roslyn J, Zhang, Alison Y, Scott, Andrew M, Lee, Sze-Ting, Azad, Arun A, McJannett, Margaret M, Stockler, Martin R, Williams, Scott G, Davis, Ian D, Hofman, Michael S, Akhurst, Tim, Alipour, Ramin, Banks, Patricia, Beaulieu, Alexis, Chua, Wei, Dhiantravan, Nattakorn, Ford, Kate, Gedye, Craig, Goh, Jeffrey C, Guminski, Alex, Hamid, Anis, Haskali, Mohammad B, Hicks, Rodney J ... for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2022). PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. The Lancet Oncology, 23 (11), 1389-1397. doi: 10.1016/S1470-2045(22)00605-2 |
|
2022 Conference Publication P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka, Stockler, Martin R., Martin, Andrew, Pashankar, Farzana, Ben Tran,, Mazhar, Danish, Huddart, Robert, Wheater, Matthew, Walpole, Euan, Dunwoodie, Elaine, Feldman, Darren, Birtle, Alison, Stevanovic, Amanda G., Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2022). P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Clinical Oncology Society of Australia (COSA) 49th Annual Scientific Meeting, Brisbane, QLD, Australia, 2-4 November 2022. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.13869 |
|
2022 Journal Article Hierarchical improvement of regional tissue oxygenation after packed red blood cell transfusionBalegar, Kiran Kumar V., Jayawardhana, Madhuka, Martin, Andrew J., de Chazal, Philip and Nanan, Ralph Kay Heinrich (2022). Hierarchical improvement of regional tissue oxygenation after packed red blood cell transfusion. PLoS One, 17 (7 July) e0271563, 7. doi: 10.1371/journal.pone.0271563 |
|
2022 Journal Article Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionalsNahm, Sharon H., Stockler, Martin R., Martin, Andrew J., Grimison, Peter, Fox, Peter, Zielinski, Rob, Hawson, Geoffrey At., Tattersall, Martin Hn. and Kiely, Belinda E. (2022). Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. Supportive Care in Cancer, 30 (9), 7763-7772. doi: 10.1007/s00520-022-07167-3 |
|
2022 Conference Publication DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiationNiazi, Tamim, McBride, Sean Matthew, Williams, Scott, Davis, Ian D., Stockler, Martin R., Martin, Andrew James, Bracken, Karen, Roncolato, Felicia, Horvath, Lisa, Sengupta, Shomik, Martin, Jarad, Lim, Tee, Hughes, Simon, McDermott, Raymond S., Catto, James W. F., Kelly, Paul J., Parulekar, Wendy R., Morgan, Scott Carlyle, Rendon, Ricardo A. and Sweeney, Christopher (2022). DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)-A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.TPS284 |
|
2022 Conference Publication TheraP: <sup>177</sup>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2022). TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-Overall survival after median follow-up of 3 years (ANZUP 1603). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Virtual, 3-7 June 2022. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2022 Journal Article ‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501)Hayne, Dickon, Grummet, Jeremy, Espinoza, David, McCombie, Steve P., Chalasani, Venu, Ford, Kate S., Frydenberg, Mark, Gilling, Peter, Gordon, Barbara, Hawks, Cynthia, Konstantatos, Alex, Martin, Andrew J., Nixon, Anthony, O’Brien, Colin, Patel, Manish I., Sengupta, Shomik, Shahbaz, Shekib, Subramaniam, Shalini, Williams, Scott, Woo, Henry H., Stockler, Martin R., Davis, Ian D. and Buchan, Nick (2022). ‘Pain-free TRUS B’: a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). BJU International, 129 (5), 591-600. doi: 10.1111/bju.15552 |
|
2022 Journal Article Reply to L. Marandino et alStockler, Martin R., Martin, Andrew J., Dhillon, Haryana M., Davis, Ian D. and Sweeney, Christopher J. (2022). Reply to L. Marandino et al. Journal of Clinical Oncology, 30 (19) JCO.22.00497, 2176-2177. doi: 10.1200/JCO.22.00497 |
|
2022 Journal Article 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II TrialPathmanandavel, Sarennya, Crumbaker, Megan, Yam, Andrew O., Nguyen, Andrew, Rofe, Christopher, Hovey, Elizabeth, Gedye, Craig, Kwan, Edmond M., Hauser, Christine, Azad, Arun A., Eu, Peter, Martin, Andrew J., Joshua, Anthony M. and Emmett, Louise (2022). 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. Journal of Nuclear Medicine, 63 (4), 560-566. doi: 10.2967/jnumed.121.262552 |
|
2022 Journal Article Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUPStockler, Martin R., Martin, Andrew J., Davis, Ian D., Dhillon, Haryana M., Begbie, Stephen D., Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy R., Pook, David W., Reaume, M. Neil, Sandhu, Shahneen, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G., Winter, Diana G. ... Sweeney, Christopher J. (2022). Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III trial led by ANZUP. Journal of Clinical Oncology, 40 (8), 837-846. doi: 10.1200/JCO.21.00941 |
|
2022 Conference Publication PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of <SUP>177</SUP>Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)Buteau, James Patrick, Martin, Andrew James, Emmett, Louise, Iravani, Amir, Sandhu, Shahneen Kaur, Joshua, Anthony M., Zhang, Alison Yan, Francis, Roslyn J., Scott, Andrew Mark, Azad, Arun, McJannett, Margaret Mary, Stockler, Martin R., Williams, Scott, Davis, Ian D. and Hofman, Michael S. (2022). PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.010 |
|
2022 Conference Publication Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1<SUP>77</SUP>LuPSMA-617 and NOX66 (LuPIN)Pathmanandavel, Sarennya, Crumbaker, Megan, Yam, Andrew O., Nguyen, Andrew, Niman, Remy, Wilson, Peter, Sharma, Shikha, Ayers, Maria, Eu, Peter, Stockler, Martin R., Martin, Andrew James, Joshua, Anthony M. and Emmett, Louise (2022). Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 177LuPSMA-617 and NOX66 (LuPIN). ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.166 |
|
2022 Conference Publication SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation scheduleHayne, Dickon, Swarbrick, Nicole, McCombie, Stephen, Moe, Andrew, Hawks, Cynthia, Viswambaram, Pravin, Conduit, Ciara, Liow, Elizabeth Chien Hern, Spalding, Lisa, Bothe, Jarrad, Ferguson, Tom, Martin, Andrew James, Davis, Ian D. and Redfern, Andrew David (2022). SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule. ASCO Genitourinary Cancers Symposium, Electr Network, Feb 17-19, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2022.40.6_suppl.483 |
